Published by Pinnacle Pulse, maker of a self-tracking app. We have no affiliate or sales relationship with any peptide seller. Editorial policy →
Tirzepatide legal status in the EU, the US and in sport
By Pinnacle Pulse Editorial Team · Status as of 16 October 2026 · Next scheduled update: 14 January 2027
Short answer: Tirzepatide is an authorized prescription medicine in the EU and the US. In May 2026 FDA proposed keeping it off the list of bulk substances that large US compounders may use, and it is no longer on FDA’s shortage list. Products labeled “for research purposes” are a target of FDA warnings. WADA monitors tirzepatide but does not prohibit it. This is general information, not legal advice.
At a glance
| Where | Status on 16 October 2026 |
|---|---|
| EU | Centrally authorized since 15 September 2022; prescription only |
| US | FDA-approved prescription drug; proposed exclusion from 503B bulks list (1 May 2026); not on FDA shortage list as of that notice |
| WADA | Not prohibited; 2027 Monitoring Program, in and out of competition |
European Union
The short version: tirzepatide is an ordinary prescription medicine in the EU. It got its marketing authorization from the European Medicines Agency’s central procedure on 15 September 2022, and that authorization is valid in every member state.
The legal trouble sits at the edges. Think of pens sold without a prescription, powders sold as “research chemicals”, or a parcel ordered from abroad.
In September 2025, EMA and the national agencies warned about a sharp rise in illegal GLP-1 medicines in the EU. That warning covers tirzepatide just as much as semaglutide. Their advice: if you buy medicines online, use a pharmacy showing the EU common logo.
United States
Tirzepatide is FDA-approved and prescription-only. FDA’s May 2026 notice mentions, almost in passing, that on 19 December 2025 tirzepatide was approved for patients aged 10 and older, in the context of blood-sugar control in type 2 diabetes.
What about compounded versions? The document to read is that Federal Register notice of 1 May 2026. In it, FDA proposed leaving tirzepatide (along with semaglutide and liraglutide) off the 503B bulks list. It also pointed out that approved tirzepatide products were not on its drug shortage list on that date. Large compounders need one or the other to work from bulk powder, so the proposal would leave them without a route. It is still a proposal. FDA extended the comment period in June 2026, and no final decision had appeared in the Federal Register by 16 October 2026.
FDA has separately warned about two kinds of fakes. One is “compounded” tirzepatide carrying the names of pharmacies that never made it. The other is tirzepatide sold straight to consumers with labels like “for research purposes” or “not for human consumption”. By 31 May 2026 the agency had more than 730 adverse-event reports involving compounded tirzepatide.
Sport
Not banned. WADA put tirzepatide, like semaglutide, in its 2027 Monitoring Program, in and out of competition, which means labs record it so WADA can decide later whether to act. When it published the 2027 list in September 2026, WADA said GLP-1 receptor agonists stay where they are while it collects more data.
What the research does not show
The approval trials tested the real medicine, with doctors following the patients. They tell you nothing about research-labeled powders or counterfeit "compounded" vials, and long-term data are still thin. Our article [Tirzepatide: what the research shows](/research/tirzepatide) has the details.FAQ
Is tirzepatide legal in the EU?
Yes, as an authorized prescription medicine. Buying it without a prescription or outside the licensed supply chain is a different matter.
Can US compounders still make tirzepatide?
FDA proposed in May 2026 not to put tirzepatide on the 503B bulks list, and it was not on the shortage list at that time. That leaves outsourcing facilities without a basis to compound it from bulk substance, pending FDA’s final decision.
Is tirzepatide banned by WADA?
No. It is in the 2027 Monitoring Program, which tracks use without prohibiting it.
Sources
- EMA. Medicines data (download of centrally authorised medicines, checked 16 October 2026). ema.europa.eu
- EMA. Warning about sharp rise in illegal medicines sold in the EU (3 September 2025). ema.europa.eu
- Federal Register, 1 May 2026, FR Doc. 2026-08552 (docket FDA-2018-N-3240). govinfo.gov
- FDA. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. fda.gov
- WADA. WADA publishes 2027 Prohibited List (21 September 2026). wada-ama.org
- USADA. Athlete advisory: what’s new on the 2027 WADA Prohibited List? usada.org
- Federal Register, 26 June 2026, FR Doc. 2026-12937: extension of the comment period for the 1 May 2026 notice, checked 16 October 2026. federalregister.gov
- Federal Register. Search of FDA documents published since 1 April 2026 for BPC-157, TB-500 and the 503A and 503B bulks lists, run 16 October 2026: no proposed or final rule. federalregister.gov
Facts last checked: 16 October 2026.
About this article
Written by: the Pinnacle Pulse Editorial Team, the people who make the Pinnacle Pulse app. We work only from primary sources such as regulators, legal texts, trial registries and PubMed, and we remove claims we can’t check against one.
This page has not been reviewed by a lawyer. It is general information, not legal advice.
Spotted an error? Our editorial policy explains how to report it and how we correct mistakes.
Change log
- 16 October 2026: First published.
From the makers of this site: Pinnacle Pulse is a neutral tracking app. We don’t sell or recommend any substance. About Pinnacle Pulse
This page is general information about the law as of the date shown. It is not legal advice. For your own situation, consult a lawyer.